Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-07-22
2011-11-15
Bristol, Lynn (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S007100, C435S326000
Reexamination Certificate
active
08058404
ABSTRACT:
Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
REFERENCES:
patent: 5858683 (1999-01-01), Keesee et al.
patent: 6303323 (2001-10-01), Laskey et al.
patent: 2003/0087270 (2003-05-01), Schlegel et al.
patent: 2003/0219726 (2003-11-01), Doorbar
patent: 2004/0202996 (2004-10-01), Williams et al.
patent: 2005/0260566 (2005-11-01), Fischer et al.
patent: WO 99/21014 (1999-04-01), None
patent: WO 02/101075 (2002-12-01), None
patent: WO 2004/013632 (2004-02-01), None
patent: WO 2005/095964 (2005-10-01), None
ATCC search output for PTA-6911 (p. 1; May 4, 2010).
Hiraiwa, A., et al., “Immunolocalization of hCDC47 Protein in Normal and Neoplastic Human Tissues and its Relation to Growth,”Int. J. Cancer, 1997, pp. 180-184, vol. 74.
Williams, G., et al., “Improved Cervical Smear Assessment Using Antibodies Against Proteins that Regulate DNA Replication,”Proc. Natl. Acad. Sci., 1998, pp. 14932-14937, vol. 95.
CDC47 / MCM7 Ab2 Data Sheet, Lab Vision, pp. 1-3, (Feb. 27, 2008).
Neomarkers Data Sheets for MCM7, Lab Vision, pp. 1-2, (Feb. 27, 2008).
Campbell et al., Biology, Fifth Edition, 1999, p. 856.
Brake, T., et al., “Comparative Analysis of Cervical Cancer in Women and in a Human Papillomavirus-Transgenic Mouse Model: Identification ofMinichromosome Maintenance Protein 7as an Informative Biomarker for Human Cervical Cancer”,Cancer Research, Dec. 2003, pp. 8173-8180, vol. 63.
Freeman, A., et al., “Minichromosome Maintenance Proteins as Biological Markers of Dysplasia and Malignancy,”Clinical Cancer Research, 1999, pp. 2121-2132, vol. 5.
Grunicke, H.H., et al., “Role and Characterization of Protein Kinase C Isoforms Implicated in the Transcriptional Activation of Cyclin D1 by Transforming HA-RAS”,Cell Biology International, 2001, pp. A16-A17, vol. 25.
Heidebrecht, H.J., et al. “Ki-Mcm6 a Monoclonal Antibody Specific for the Human Minichromosome Maintenance Protein 6 (Mcm6)”,Joint Annual Meeting, 2000, p. 406, University of Kiel and University of Hamburg, Germany.
Helfenstein, A., et al., “Minichromosome Maintenance Protein (MCM6) in Low-Grade Chondrosarcoma”,Am. J. Clin. Pathology, 2004, pp. 912-918, vol. 122.
Ishimi, Y., et al , “Enhanced Expression of Mcm Proteins in Cancer Cells Derived from Uterine Cervix”,Eur. J. Biochem., Feb. 2003, pp. 1089-1101, vol. 270.
Lederman, S., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,”Molecular Immunology, 1991, pp. 1171-1181, vol. 28(11).
Li, C.H., et al., “β-Endorphin Omission Analogs: Dissociation of Immunoreactivity From Other Biological Activities,”Proc. Natl. Acad. Sci., 1980, pp. 3211-3214, vol. 77(6).
Malinowski, D.P., “Molecular diagnostic Assays for Cervical Neoplasia: Emerging Markers for the Detection of High-Grade Cervical Disease”,BioTechniques, Apr. 2005, pp. 17-23, vol. 38.
Paul, W.E.,Fundamental Immunology, 1993, vol. 242.
Schrader, C., et al., “Minichromosome Maintenance Protein 6, a Proliferation Marker Superior to Ki-67 and Independent Predictor of Survival in Patients with Mantle Cell Lymphoma”,British Journal of Cancer, 2005, pp. 939-945, vol. 93.
Heidebrecht, H.J., et al., “MCM6 Distribution in Proliferating Cells Detected by the Novel MAB KI-MCM6,”Cell Biology International, 2001, pp. A16-A17, vol. 25(2).
Heidebrecht, H.J., et al., “Ki-Mcm6, a New Monoclonal Antibody Specific to Mcm6: Comparison of the Distribution Profile of Mcm6 and the Ki-67 Antigen,”Laboratory Investigation, 2001, pp. 1163-1165, vol. 81(8).
NCBI GenBank Report for Accession No. NP—005906, Direct Submission on Mar. 2, 2005.
Li, H., et al., “Abstract #4886—Quantitative Molecular Analysis of MCM-6 as a Specific Biomarker for Cervical Disease Diagnosis,”Proc. Amer. Assoc. Cancer Res., 2005, vol. 46.
Chen, Y., et al., “Identification of Cervical Cancer Markers by cDNA and Tissue Microarrays,”Cancer Research, 2003, pp. 1927-1935, vol. 63.
Fischer Timothy J.
Malinowski Douglas P.
Taylor Adriann J.
Alston & Bird LLP
Bristol Lynn
Tripath Imaging, Inc.
LandOfFree
MCM6 and MCM7 monoclonal antibodies and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCM6 and MCM7 monoclonal antibodies and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCM6 and MCM7 monoclonal antibodies and methods for their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261943